Pacaña, Berlinda S.

HRN: 23-65-95  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/08/2023
CEFUROXIME 1.5GM (VIAL)
09/08/2023
09/14/2023
IV
1.5g
Q8
UTI
09/08/2023
CEFTRIAXONE 1G (VIAL)
09/08/2023
09/14/2023
IV
2g
OD
UTI
Checking Final Appropriateness 
09/09/2023
LEVOFLOXACIN 5MG/ML, 100ML (VIAL)
09/09/2023
09/13/2023
IV
500
OD
CAP MR
Checking Final Appropriateness 
09/16/2023
MUPIROCIN 2%, 15G (TUBE)
09/16/2023
09/23/2023
TOPICAL
2%
BID
Decubitus Ulcer
Checking Final Appropriateness 
09/20/2023
CEFUROXIME 1.5GM (VIAL)
09/20/2023
09/26/2023
IV
1.5gm
Q8
Acute Uncomplicated UTI
09/28/2023
CEFTRIAXONE 1G (VIAL)
09/28/2023
10/04/2023
IV
2g
OD
UTI
Checking Final Appropriateness 
09/29/2023
MUPIROCIN 2%, 15G (TUBE)
09/29/2023
10/05/2023
TOPICAL
Apply On Skin
BID
Pressure Ulcer
Checking Final Appropriateness 

AMS Audit Form


Start Date: End Date:

 Indication:

              

 Type of Infection:

                             

           

 Compliance to guidelines:



 Initial appropriateness:



 If inappropriate:

           

 Final appropriateness:



 If inappropriate:

              

 Overall appropriateness: